{"prompt": "['REduCing Immunogenicity to PegloticasE (RECIPE)', 'Protocol #Version v12: 13Jan2020', '1', 'STATEMENT OF COMPLIANCE', 'The REduCing Immunogenicity to PegloticasE (RECIPE) trial will be conducted in accordance with the', 'International Conference on Harmonization Good Clinical Practice (ICH GCP), applicable United States', '(US) Code of Federal Regulations (CFR), and National Institute of Arthritis and Musculoskeletal and Skin', 'Diseases (NIAMS) Terms and Conditions of Award. The Principal Investigator (Kenneth Saag, MD, MSc)', 'will ensure that no deviation from, or changes to the protocol will take place without prior agreement', 'from the NIAMS, and documented approval from the Institutional Review Board (IRB), except where', 'necessary to eliminate an immediate hazard(s) to the trial participants. All personnel involved in the', 'conduct of this study have completed Human Subjects Protection and ICH GCP Training.', 'The protocol, informed consent form(s), recruitment materials, and all participant materials have been', 'submitted and approved by the University of Alabama at Birmingham (UAB) Institutional Review Board', '(IRB) and vetted with the Food and Drug Administration (FDA) per the investigation new drug (IND)', 'review. Any amendment to the currently approved protocol will require review and approval by the IRB', 'before the changes are implemented to the study. All changes to the consent form will be IRB', 'approved; in be obtained from any participants who provided consent, using a previously approved', 'consent form.', '2', 'PROTOCOL SUMMARY', '2.1 SYNOPSIS', 'Title:', 'Reducing Immunogenicity to Pegloticase (RECIPE)', 'Study Description:', 'Pegloticase treatment for chronic refractory gout is limited by', 'immunogenicity. The investigators propose the REduCing Immunogenicity', 'to PegloticasE (RECIPE) trial to investigate the question of whether a short', 'course of immune modulating therapy with mycophenolate mofetil (MMF)', 'can significantly and safely attenuate immunogenicity to pegloticase and', 'ensure patients afflicted with chronic refractory gout have better', 'treatment outcomes and improved quality of life.', 'Objectives:', 'Evaluate feasibility and preliminary efficacy and safety of a short course of', 'immunosuppressive therapy to prevent immunogenicity conferred by', 'pegloticase.', 'Endpoints:', 'Primary Endpoints: The co-primary aims of our proof-of-concept double-', 'blind study are to first assess the feasibility and preliminary efficacy of a', 'short course of immune modulating therapy with daily mycophenolate', 'mofetil (MMF). We will explore the future full-scale study hypothesis that', 'administering MMF for 12 weeks can safely attenuate immunogenicity', 'conferred by pegloticase as determined by the proportion of participants', 'achieving and maintaining a serum urate (sUA) < to 6 mg/dL for 12 weeks,', 'compared to concurrent controls. After 12 weeks of co-administration of', 'MMF with pegloticase or placebo, all participants will continue on', 'pegloticase for an additional 12 weeks without combination MMF therapy', 'to evaluate the longer-term benefits and safety of this approach. The', 'second co-primary safety aim will assess the incidence and types of', 'adverse events/infusion reactions potentially associated with MMF.', 'Secondary Endpoints: 1) Determine the 6 month durability of immune', 'modulation after discontinuation of the short course of MMF by: a)', '1']['REduCing Immunogenicity to PegloticasE (RECIPE)', 'Protocol #Version v12: 13Jan2020', 'assessing the absolute change in serum urate from baseline to Week 24,', 'and Week 12 to Week 24, and b) determining the proportion of', 'participants with serum urate 6 mg/dL through 24 weeks, and Week 12', 'to Week 24; 2) Identify and characterize the pegloticase immune response', 'by immunoglobulin isotypes (IgG and IgM), specificities, and antibody titer,', 'and 3) Examine patient reported outcomes (PROs) using the National', 'institute of Health (NIH) supported Patient Reported Outcomes', 'Measurement Information System (PROMIS) and Gout Impact Scale (GIS)', 'instruments.', 'Study Population:', 'We will enroll 32 adults (> 18 years of age) diagnosed with chronic', 'refractory gout, defined as persons whose signs and symptoms are', 'inadequately controlled with urate lowering therapy (e.g. xanthine oxidase', 'inhibitors or uricosuric agents) at a medically appropriate dose or for', 'whom these drugs are contraindicated. Recruitment will include men and', 'women of all races/ethnicities.', 'Phase:', 'Phase II Trial', 'Description of', 'University of Alabama at Birmingham (Study Clinical Coordinating Center', 'Sites/Facilities Enrolling', 'and Data Coordinating Center); University of Michigan.', 'Participants:', 'Description of Study', 'Phase II, double blind, placebo controlled multisite proof-of-concept trial', 'Intervention:', 'in participants initiating pegloticase for treatment of chronic refractory', 'gout. Participants will be randomized (3:1) to one of two study arms, a', 'pegloticase + MMF or a pegloticase + placebo study arm study arm.', 'Experimental: pegloticase + MMF', 'Participants randomized to this arm will receive pegloticase + MMF', 'Placebo Comparator: pegloticase + placebo (PBO)', 'Participants randomized to this arm will receive pegloticase + placebo', 'Study Duration:', '24 months', 'Participant Duration:', 'Up to six months (24 weeks)', '2.2 SCHEMA', 'Figure 1. RECIPE Study Patient Level Timeline', 'Pegloticase+ PBO (2g)', '(n=8)', 'MMF (start', 'Follow', 'Screen and', 'Pegloticase only (n = 32 )', '1g/PBO', 'Randomize', 'Up', 'Run-in', 'Pegloticase + MMF (2g)', '(n =24)', '-2', 'WK 0 1 2 3 WK 4', '6', 'WK8', '10', 'WK12', '14', 'WK 16', '18', 'WK 20', '22', 'WK 24', 'WK', 'WK', 'WK', '(Baseline)', '(1\u00b0 Data Point)', '28', '32', '36', '2']\n\n###\n\n", "completion": "END"}